恩曲他滨
医学
养生
内科学
聚乙二醇干扰素
胃肠病学
HBeAg
临床终点
聚乙二醇干扰素α-2a
替诺福韦
α-干扰素
乙型肝炎病毒
拉米夫定
病毒学
人类免疫缺陷病毒(HIV)
慢性肝炎
临床试验
干扰素
乙型肝炎表面抗原
病毒
利巴韦林
作者
José Antonio Mata‐Marín,Luis Alberto Mata-Marín,Carla Ileana Arroyo-Anduiza,Gloria Huerta-García,Jorge Luis Sandoval-Ramírez,Bulmaro Manjarrez-Téllez,JE Gaytán‐Martínez
出处
期刊:PubMed
日期:2014-12-02
卷期号:61 (133): 1187-91
被引量:1
摘要
The most common HBV genotypes in HIV-coinfected patients in Mexico are H and G; the response to treatment for these genotypes is unknown. The aim of the study was to examine the effectiveness of intensification with pegylated interferon (PEG-IFN) alfa-2a or alfa-2b in HBV/HIV-coinfected patients treated with a tenofovir/emtricitabine (TDF/FTC) backbone in an HIV clinic in Mexico City.We performed a single-arm open-label trial involving HBV/HIV-coinfected patients. Patients with chronic hepatitis B who were HBeAg positive were treated with TDF/FTC-containing regimen. Treatment was intensified by addition of PEG-IFN alfa-2b or alfa-2a for 24 weeks. The primary endpoint of effectiveness, assessed after 24 weeks, was suppression of HBV DNA to <60 IU/mL.We enrolled 29 patients; 27 (93%) were men. HBV genotypes were F in 2 (6.9%), A in 2 (6.9%), G in 10 (34.5%), and H in 15 (51.7%). The primary endpoint was present in 17 (58%) patients (95% CI 29.7%–70.8%).Intensification with PEG-IFN alfa-2a or alfa-2b is effective and well tolerated in patients with chronic hepatitis B who are HBeAg positive, have genotype H or G, and are coinfected with HIV while they are being treated with TDF/FTC-containing regimen.
科研通智能强力驱动
Strongly Powered by AbleSci AI